Aviva Tobin-Hess
Internal Medicine · Woodmere, NYNPI 1598297376
Payments from drug & device makers
Across 45 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$234
- E.r. Squibb & Sons, L.L.C.$128
- Heartflow, Inc.$69
- Lilly USA, LLC$60
- Boehringer Ingelheim$55
- Astellas Pharma US Inc$53
- plus $341 from 16 others
What the payments were for
- Food & beverage$939100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $234 |
| E.r. Squibb & Sons, L.L.C. | 1 | $128 |
| Heartflow, Inc. | 2 | $69 |
| Lilly USA, LLC | 4 | $60 |
| Boehringer Ingelheim | 3 | $55 |
| Astellas Pharma US Inc | 3 | $53 |
| Sanofi Pasteur Inc. | 3 | $46 |
| Novo Nordisk | 2 | $39 |
| Almatica Pharma LLC | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Amgen | 1 | $20 |
| Merck | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Pfizer | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| GSK | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Bavarian Nordic A/s | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$128
How this compares
$939 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PaxlovidNirmatrelvir/Ritonavir | 18 | $2,859 |
| Levothyroxine Sodium | 11 | $478 |
| Cefdinir | 22 | $442 |
| Zolpidem Tartrate | 28 | $249 |
| Azithromycin | 47 | $234 |
| Doxycycline Hyclate | 21 | $203 |
| Atorvastatin Calcium | 19 | $188 |
| Pantoprazole Sodium | 11 | $147 |
| Alprazolam | 14 | $122 |
| Rosuvastatin Calcium | 11 | $116 |
| Hydrochlorothiazide | 11 | $100 |
| Amlodipine Besylate | 14 | $51 |
| Prednisone | 12 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPaxlovid | $17 | $2,85918 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $47811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Woodmere
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.